The company's platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and informing physician decisions. Founded in 2013 and headquartered in Branford, Connecticut, IsoPlexis Corp accelerates insights in the field of cancer by revealing functional protein biology and cellular signaling networks at single-cell resolution to advance the development of advanced medicines for immune medicine, promising a lasting and durable impact on many diseases.